Jun 3, 2013
1) Creation of the AAN Global Health Section and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Amy Lee about her paper on the creation of the AAN Global Health Section. Dr. Adam Numis is reading our e-Pearl of the week about Tullio phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jerome Posner about receiving the 2013 President's Award at the AAN Meeting and discussing his lecture on the importance of teaching and mentoring in neurology. The participants had nothing to disclose except Drs. Mateen, Numis, Espay and Posner.Dr. Mateen has consulted for the World Health Organization, Global Polio Eradication Initiative, and Caritas.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Posner serves as an editorial board member on Up-to-Date; receives royalties from the publications of the books Diagnosis of stupor and coma and Neurologic complications of cancer; receives royalty payments, technology/inventions from Athena diagnostics.